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Undiscovered morphine. The effects 
of the long-term use of the opioids
Abstract
Morphine and other opioids are used much more often and for a longer time than before. This causes many 
relatively unknown adverse effects, which become apparent only after a while. One of them is opioid-in-
duced hyperalgesia and abnormal magnesium metabolism. The adverse effect that negatively influences 
the quality of life is opioid-induced hypogonadism. Morphine can have a profound immunosuppressive 
and tumour-promoting effect. It is probably responsible for the increased rate of heart infarctions. Very 
interesting are suggestions that morphine and other opioids are changing the large bowel microbiome. 
All of these phenomena do not concern only few patients but are generalized in this population and the 
severity of the phenomenon depends only on the treatment period. Jet none of these adverse effects are 
mentioned in drug leaflets. All of these phenomena are treatable providing that the diagnose is made 
accurately and timely. It is very well possible that in the future we shall be able to prevent most of these 
adverse effects.
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Introduction
Morphine as a component of opium is known in 
medicine for 6,000 years. For more than 200 years 
it is used as a pure drug. Since the time morphine 
became a part of modern medicine, it is well known 
that considerable adverse effects always accompany 
its analgesic effect. These adverse effects like con-
stipation, nausea and vomiting and deterioration 
of cognitive functions are known to every medical 
student. However, some of the adverse effects are 
less well known, and they are never mentioned on the 
drug leaflets. These adverse effects are not known at 
all and never discussed with the patients before the 
beginning of therapy. We use more and more opioids, 
not only for the control of pain in the course of the 
malignant disease [1].
Because patients with cancers live much longer 
than a couple of decades ago, probably they use opi-
oids for a longer time than before. Formerly opioids 
were used for a couple of weeks to months only and 
this period invariably ended in the patients’ death. 
Nowadays we have quite a large group of cancer 
survivors among whom opioids need to be used for 
a longer time, sometimes for years [2]. Above all, 
in the USA, and not only there, it also appears that 
there is a considerable group of patients treated 
with opioids for non-malignant conditions [1]. This 
all makes that we should think about the long-term 
effects of opioids.
www.journals.viamedica.pl/palliative_medicine_in_practice 23
Zbigniew Żylicz, Undiscovered morphine. The effects of the long-term use of the opioids
Tolerance and Hyperalgesia 
Tolerance to opioids is known to clinicians for de-
cades. Opioids are very successful at the beginning. 
However, their efficacy diminishes rapidly. To obtain 
the same analgesic effects clinicians must increase the 
dose of the drug [3]. This phenomenon is rare when 
the treatment is short, for example postoperatively, 
but becomes considerable when the drug is used 
for a long while, especially in genetically susceptible 
patients [4]. In the past, some influential authors sug-
gested that the opioid tolerance could be prevented 
by using it “by the clock”, which means that the next 
dose should be administered before the effect of the 
first dose will wean [5].
Unfortunately, this way of administration was 
not entirely successful either. Continuous morphine 
and other opioids administration induce changes in 
glutaminergic transmission [6] and excitation of the 
N-methyl-D-aspartase (NMDA) receptors [7]. These 
changes can be counteracted by the NMDA-inhibitor; 
ketamine [8, 9].
Tolerance to opioids has much in common with 
Opioid-Induced Hyperalgesia (OIH) which is defined 
as a nociceptive sensitisation caused by exposition to 
opioids [10]. The clinicians can easily mix up those two 
phenomena. In the case of OIH, the opioid given to the 
patient not only causes analgesia but is the cause of 
a “new pain” due to the spinal excitation.  If this “new 
pain” is not explicitly recognised it would cause, simi-
larly to opioid tolerance, the need for an opioid dose 
increase. The differences between tolerance and IOH 
are discrete. This “new pain” maybe, but not neces-
sarily, be similar to the original pain. The original pain 
may be already efficaciously treated by the opioid. The 
patient shows increased sensitivity to pain impulses 
[11]. Investigations on the large patient populations 
showed that patients treated with opioids are more 
sensitive to pain impulses compared to the patients 
treated with non-opioid analgesics [12]. The reader 
interested in the problems around OIH is referred to 
specific publications [13, 14].
Management of OIH is usually based on making 
a specific diagnosis and decrease of the opioid dose 
[15]. If this is impossible, or for the patient and its 
family counter-intuitive, the opioid may be switched 
from for example morphine or fentanyl to the opioids 
with less potential of producing OIH — buprenorphine 
[16] or methadone [17]. In any case, the clinicians 
should refrain from using the mega opioid doses[18], 
which were so popular only two decades ago. An-
other strategy could be the addition of NSAIDs or 
paracetamol [19].
Hypogonadism induced by opioids
Already after the first dose opioids inhibit the 
secretion of the pituitary gonadotrophins [20]. Pro-
longed opioid administration may lead to hypogo-
nadism, as well in man as women [21–23]. Deficiency 
of testosterone and other sex hormones manifests 
itself as fatigue, anaemia, increased sensitivity to pain 
stimuli, muscular atrophy, osteoporosis, erectile and 
menstrual cycle dysfunction. In total, hypogonadosm 
translates into a lower quality of life of patients treated 
with opioids [24]. The management is straightforward 
and not very toxic. Terminally ill patients may be 
treated with testosterone [25]. However, it should be 
born in mind that testosterone deficiency may cause 
insensitivity to opioids [26]. Administration of testos-
terone rapidly changes this to increased sensitivity to 
opioids which may result in an unexpected respiratory 
depression [25]. It seems, for obvious reason, there is 
a consensus not to prescribe testosterone to patients 
with prostate and breast cancers.
Osteoporosis
Long term administration of opioids, probably 
induces bone decalcification and osteoporosis and 
decalcification translates in an increased risk of bone 
fractures [27, 28]. However, in falls, other factors as 
weakness and disturbances of consciousness may 
play a role too.
Disorders of magnesium metabolism
Magnesium is one of the most critical ions involved 
in pain origination and transmission [29]. It plays 
a vital role in muscle and bone metabolism as well 
as in the metabolism of carbohydrates. Deficiency 
of this ion causes among others opening of the 
NMDA ion channels and promotes their activation 
[30] which translates in pro-nociceptive activity. Long 
term treatment with morphine causes increased renal 
magnesium excretion and hypomagnesaemia [31]. 
On the other hand, the administration of magnesium 
sulfate together with morphine considerably increases 
morphine analgesic effect [32]. In the meta-analysis of 
multiple trials with magnesium sulfate and morphine, 
this effect was confirmed beyond any doubt [32, 33].
Effects of opioids on the tumour 
growth
Morphine has an immunosuppressive effect and 
increases proliferation and migration of the tumour 
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cells as well as it promotes tumour angiogenesis [34]. 
In this respect, morphine is the most immunosuppres-
sive of all opioids [35] and least immunosuppressive is 
buprenorphine [36]. That in case of terminally ill the 
immunosuppressive effects of opioids is the least of 
concerns, but in many thousands of cancer survivors 
that need to be treated with analgesics for a long 
time, it may be of paramount importance.
Nocturnal breathing disorders
Patients treated with opioids for chronic pain have 
a high probability of nocturnal apnea and hypoxemia 
[37]. Resting hypoxemia can be observed in these 
patients also in the day time, especially after the 
awakening [37].
Cardiovascular diseases
Not much is known about the influence of opioids 
on cardiovascular diseases. In one large cohort cover-
ing 297 314 patients [38], and receiving opioids for 
at least 180 days in 3.5 years the Adjusted Incidence 
Rate Ratio (AIRR) of myocardial infarction was mod-
erately increased and equal to 2.66 (CI, 2.30 to 3.08). 
Patients prescribed opioids at the cumulated MEDD 
(Morphine Equivalent Daily Dose) of 1350 mg during 
90 days the AIRR was 1.21 (CI, 1.02 to 1.45) while 
the AIRR in patients treated with a MEDD between 
1350-2700 mg in 90 days was calculated as 1.42 up 
to 1.89. These risk values are higher than the risk of 
myocardial infarction after treatment with ibuprofen 
of diclofenac [39].
Gastrointestinal disorders
Opioids are known to affect the delay in gastric 
emptying and slow the intestinal movements which 
result in increased nausea and vomiting as well as 
constipation. Opioids are also known to change the 
bacterial content of the large bowel [40]. In patients 
addicted to opioids, there is a remarkable deficit of 
Bifidus and Prevotella sp. bacteria. This phenomenon 
may influence the development of psychological de-
pression [41] and cancer cachexia [42] as well as many 
other symptoms accompanying neoplastic diseases.  
Conclusions
The consumption of opioids, including morphine, 
increases year by year. These data include not only 
the treatment of pain in the course of cancer but 
also the treatment of non-cancer pain. Some patients 
use morphine and other opioids for a more extended 
period. In this situation, it is essential to consider the 
long-term effects of treatment with morphine and 
other opioids. Besides well-known more or less acute 
adverse effects of morphine and other opioids, there 
are some less well-known long-term effects which are 
a problem only after more extended use.
The most important is the development of OIH and 
disturbance of magnesium metabolism and excretion. 
Here morphine is the cause of new pain and suffering, 
which without a specific diagnosis usually ends up in 
the increase of opioid dose and treatment failure.   If 
the diagnosis of OIH is correctly made the first-choice 
treatment is decreasing and not increasing the dose. 
Another strategy is to swap one opioid of the higher 
IOH potential to buprenorphine or methadone.
After OIH, the often occurring and rarely rec-
ognised hypogonadism is very important for the 
quality of life of patients. Here, we should probably 
sooner substitute with testosterone. In women, this 
can lead to unpleasant virilisation. It is essential, how-
ever, to realise that these adverse effects do not occur 
only in some but in virtually all patients. The extent 
of the phenomenon probably depends on genetics, 
dose and the duration of opioid treatment.  It looks 
like buprenorphine has the most interesting profile in 
this aspect and is suitable as no one other opioid for 
the long term treatment [43]. Exciting is the change 
in microbiome in large bowel under the influence of 
opioids. Perhaps this is the key to the understanding 
of many ailments related to long-term use of opioids.
Does this all mean that we should use fewer opi-
oids instead of more? Yes and No. For sure, where 
opioids can be replaced by other drugs or non-drugs 
methods of treatment, this should be done at once. 
On the other hand, physical rehabilitation in palliative 
medicine has great potential and should be further de-
veloped [44, 45]. Intensive rehabilitation is associated 
with the reduction of opioid doses and decrease of 
intensity of pain [46]. On the other hand, we should 
not overreact, because still numerous patients remain 
undertreated with opioids.
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